284 related articles for article (PubMed ID: 38401905)
1. Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.
Fujiwara Y; Kato S; Kurzrock R
Surg Oncol Clin N Am; 2024 Apr; 33(2):197-216. PubMed ID: 38401905
[TBL] [Abstract][Full Text] [Related]
2. The molecular tumor board: a tool for the governance of precision oncology in the real world.
Incorvaia L; Russo A; Cinieri S
Tumori; 2022 Aug; 108(4):288-290. PubMed ID: 34918610
[TBL] [Abstract][Full Text] [Related]
3. [Precision oncology and molecular tumor boards].
Mack E; Horak P; Fröhling S; Neubauer A
Inn Med (Heidelb); 2024 May; 65(5):462-471. PubMed ID: 38652307
[TBL] [Abstract][Full Text] [Related]
4. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
5. Molecular tumour boards - current and future considerations for precision oncology.
Tsimberidou AM; Kahle M; Vo HH; Baysal MA; Johnson A; Meric-Bernstam F
Nat Rev Clin Oncol; 2023 Dec; 20(12):843-863. PubMed ID: 37845306
[TBL] [Abstract][Full Text] [Related]
6. Tissue-Agnostic Cancer Therapy Approvals.
Gouda MA; Subbiah V
Surg Oncol Clin N Am; 2024 Apr; 33(2):243-264. PubMed ID: 38401908
[TBL] [Abstract][Full Text] [Related]
7. [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges].
Holch JW; Westphalen CB; Hiddemann W; Heinemann V; Jung A; Metzeler KH
Dtsch Med Wochenschr; 2017 Nov; 142(22):1676-1684. PubMed ID: 29078213
[TBL] [Abstract][Full Text] [Related]
8. [Personalized medicine in oncology].
Lörsch AM; Jung J; Lange S; Pfarr N; Mogler C; Illert AL
Pathologie (Heidelb); 2024 May; 45(3):180-189. PubMed ID: 38568256
[TBL] [Abstract][Full Text] [Related]
9. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
10. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
[TBL] [Abstract][Full Text] [Related]
11. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
[TBL] [Abstract][Full Text] [Related]
12. Precision diagnostics: integration of tissue pathology and genomics in cancer.
Sharma S; George P; Waddell N
Pathology; 2021 Dec; 53(7):809-817. PubMed ID: 34635323
[TBL] [Abstract][Full Text] [Related]
13. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
14. Molecular screening programs in different countries: what we learned and perspectives.
Borcoman E; Le Tourneau C; Kamal M
Curr Opin Oncol; 2019 Sep; 31(5):445-453. PubMed ID: 31261171
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
[TBL] [Abstract][Full Text] [Related]
16. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.
Louie BH; Kato S; Kim KH; Lim HJ; Lee S; Okamura R; Fanta PT; Kurzrock R
Mol Oncol; 2022 Jul; 16(13):2575-2584. PubMed ID: 35238467
[TBL] [Abstract][Full Text] [Related]
18. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
[TBL] [Abstract][Full Text] [Related]
19. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
20. The role of molecular tumor boards in neuro-oncology: a nationwide survey.
Hönikl LS; Lange S; Butenschoen VM; Delbridge C; Meyer B; Combs SE; Illert AL; Schmidt-Graf F
BMC Cancer; 2024 Jan; 24(1):108. PubMed ID: 38243190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
